Abstract
The tumor suppressor protein p53 is overexpressed in close to 50% of all human malignancies. The p53 protein is therefore an attractive target for immunotherapy. Cytotoxic T lymphocytes (CTLs) recognizing a murine wild-type p53 peptide, presented by the major histocompatibility complex class I molecule H-2K(b), were generated by immunizing p53 gene deficient (p53 -/-) C57BL/6 mice with syngeneic p53-overexpressing tumor cells. Adoptive transfer of these CTLs into tumor-bearing p53 +/+ nude mice caused complete and permanent tumor eradication. Importantly, this occurred in the absence of any demonstrable damage to normal tissue. When transferred into p53 +/+ immunocompetent C57BL/6 mice, the CTLs persisted for weeks in the absence of immunopathology and were capable of preventing tumor outgrowth. Wild-type p53-specific CTLs can apparently discriminate between p53-overexpressing tumor cells and normal tissue, indicating that widely expressed autologous molecules such as p53 can serve as a target for CTL-mediated immunotherapy of tumors.
Cite
CITATION STYLE
Vierboom, M. P. M., Nijman, H. W., Offringa, R., Van DerVoort, E. I. H., Van Hall, T., Van Den Broek, L., … Melief, C. J. M. (1997). Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Journal of Experimental Medicine, 186(5), 695–704. https://doi.org/10.1084/jem.186.5.695
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.